Sight Sciences (NASDAQ:SGHT – Get Free Report) and OrthoPediatrics (NASDAQ:KIDS – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership.
Earnings and Valuation
This table compares Sight Sciences and OrthoPediatrics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sight Sciences | $79.55 million | 3.61 | -$38.43 million | ($0.71) | -7.44 |
| OrthoPediatrics | $236.35 million | 2.05 | -$39.65 million | ($1.68) | -11.21 |
Institutional and Insider Ownership
55.5% of Sight Sciences shares are owned by institutional investors. Comparatively, 69.1% of OrthoPediatrics shares are owned by institutional investors. 30.9% of Sight Sciences shares are owned by company insiders. Comparatively, 32.7% of OrthoPediatrics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Sight Sciences and OrthoPediatrics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sight Sciences | -46.83% | -52.34% | -28.49% |
| OrthoPediatrics | -16.31% | -7.01% | -4.86% |
Analyst Recommendations
This is a summary of recent recommendations and price targets for Sight Sciences and OrthoPediatrics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sight Sciences | 1 | 3 | 5 | 0 | 2.44 |
| OrthoPediatrics | 1 | 1 | 9 | 0 | 2.73 |
Sight Sciences presently has a consensus price target of $8.14, indicating a potential upside of 54.09%. OrthoPediatrics has a consensus price target of $24.44, indicating a potential upside of 29.81%. Given Sight Sciences’ higher possible upside, equities analysts plainly believe Sight Sciences is more favorable than OrthoPediatrics.
Risk & Volatility
Sight Sciences has a beta of 2.41, suggesting that its stock price is 141% more volatile than the S&P 500. Comparatively, OrthoPediatrics has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500.
Summary
OrthoPediatrics beats Sight Sciences on 8 of the 14 factors compared between the two stocks.
About Sight Sciences
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.
About OrthoPediatrics
OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediguard, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIMTM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIROTM Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, and Mitchell Ponseti. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.
Receive News & Ratings for Sight Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sight Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
